Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05791071 · ClinicalTrials.gov registry record · Phase 2
Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD)
A Phase 2 study, sponsored by Floreo.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT05791071: Completed Phase 2 study, sponsored by Floreo.
NCT05791071 is a Phase 2 study that has completed, run by Floreo. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05791071, a Phase 2 study, has completed, sponsored by Floreo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
A Randomized Controlled Phase II study to assess the efficacy of Floreo VR (Virtual reality) Building Social Connections as treatment for social skills in children with Autism Spectrum Disorder (ASD)
Primary Outcome
The AIM is a 25-item parent questionnaire targeting sensitivity to change of core ASD symptoms. The questionnaire uses a 2-week recall period with items rated on two corresponding 5-point scales (frequency and impact). The items cover distinct sub-domains of ASD symptoms including Repetitive Behavior, Atypical Behavior, Social Reciprocity, and Peer Interaction. A composite score is also calculated.
Interventions
- DEVICE Sham
- DEVICE Floreo VR Building Social Connections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 2 |
What the finished NCT05791071 record still lists
NCT05791071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT05791071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05791071 about?
NCT05791071 is a clinical study titled "Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD)". A Randomized Controlled Phase II study to assess the efficacy of Floreo VR (Virtual reality) Building Social Connections as treatment for social skills in children with Autism Spectrum Disorder (ASD)
What is the current status of trial NCT05791071?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-02-15. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT05791071?
The interventions under investigation include: Sham (DEVICE), Floreo VR Building Social Connections (DEVICE).
Who is sponsoring clinical trial NCT05791071?
This trial is sponsored by Floreo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05791071's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI